Posted by Sam Fenny - Memes and headline comments by David Icke Posted on 26 October 2023

Feed them shit food to make them fat then you can give them yet another jab: Drug Makers Now Targeting 6-Year-Olds With Popular Weight-Loss Shots

The makers of three popular weight loss drugs, all of which have known physical and mental health risks, announced last week that they are testing the products for children as young as age 6.

Novo Nordisk, maker of Ozempic and Wegovy, and Eli Lilly, maker of Mounjaro, have approval for the drugs in the U.S. and European Union (EU) for people ages 12 and up.

Novo Nordisk is reportedly already in phase 3 trials with children 6-12, testing its Saxenda product, an older and less potent version of its bestselling drugs. Eli Lilly began recruiting children for its trials last week.

An Eli Lilly spokesperson told Bloomberg, “We are certainly committed to innovation in this space that’s going to address all segments of the population that’s affected.”

Commenting on the plans for marketing Ozempic and Mounjaro to younger children, nutritionist Carrie Lupoli told NewsNation:

“It’s scary to me that we are going down that path instead of actually working on the root cause because we know weight gain is a symptom of health and hormones. …

“This isn’t going to help us get healthier as a nation and it’s going to perseverate this ‘lose weight by any means’ mindset.”

Semaglutide, the active ingredient in Ozempic and Wegovy, liraglutide, the active ingredient in Saxenda, and tirzepatide, the active ingredient in Mounjaro, all belong to the class of drugs called incretin mimetics.

They are designed to mimic the body’s natural insulin-releasing hormone that people with Type 2 diabetes or obesity are either missing or have in short supply.

All three drugs function as glucagon-like peptide-1 (GLP-1) receptor agonists. The GLP-1 hormone helps regulate blood sugar levels by inducing the pancreas to release insulin, which helps the body process glucose (sugar) for energy.

The drugs attach to the same receptors as GLP-1, causing the body to release more insulin when we eat, which — unless we are insulin-resistant — lowers blood sugar levels.

Mounjaro’s tirzepatide, called a “dual co-agonist” medicine, also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor, potentially providing a more robust insulin response, with greater suppression of glucagon and enhanced weight loss effects.

Dr. Ibiye Owei, assistant professor at Texas Tech University Health Sciences Center El Paso, told Healthline that semaglutide “works by making people feel full sooner … by slowing emptying the stomach so there is a feeling of satiety.”

The drugs also suppress the appetite and reduce cravings. Although the mechanisms are not fully understood, scientists point to GLP-1 receptors in various regions of the brain involved in the regulation of appetite and reward — in particular the suppression of dopamine signaling that affects the relationship between food and pleasure.

These drugs also have been shown to have other health-promoting effects, such as lowering blood pressure, improving blood flow to the heart, reducing the risk of heart attack and stroke, and protecting pancreatic cells.

The U.S. Food and Drug Administration (FDA) in 2020 approved Ozempic for reducing the risk of heart attacks and strokes.

The drugs typically come in liquid form and are self-administered weekly through injections to the belly, outer thighs, upper buttocks or the backs of the arms.

Read More: Drug Makers Now Targeting 6-Year-Olds

The Dream

From our advertisers